<i>KRAS</i> G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

Fu, Xin-Hui; Chen, Zhi-Ting; Wang, Wen-Hui; Fan, Xin-Juan; Huang, Yan; Wu, Xiao-Bin; Huang, Jing-Lin; Wang, Jing-Xuan; Lin, Han-Jie; Tan, Xiao-Li; Wang, Lei; Wang, Jian-Ping

doi:10.7150/jca.27899



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(4):821-828. doi:10.7150/jca.27899 This issue Cite

Research Paper

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients

Xin-Hui Fu^1,2,3,*, Zhi-Ting Chen^1,2,3,*, Wen-Hui Wang^4,*, Xin-Juan Fan³, Yan Huang³, Xiao-Bin Wu⁵, Jing-Lin Huang^1,2,3, Jing-Xuan Wang^1,2,3, Han-Jie Lin^1,2,3, Xiao-Li Tan^1,2,3, Lei Wang^5✉, Jian-Ping Wang^1,2✉

1. Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China
2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China
3. Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China
4. Department of Information and Technology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China
5. Department of GI Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, China
^* These authors have contributed equally to this work.

Citation:

Fu XH, Chen ZT, Wang WH, Fan XJ, Huang Y, Wu XB, Huang JL, Wang JX, Lin HJ, Tan XL, Wang L, Wang JP. KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. J Cancer 2019; 10(4):821-828. doi:10.7150/jca.27899. https://www.jcancer.org/v10p0821.htm

Other styles

Abstract

This study aims to investigate the molecular characteristics of Chinese gastric cancer patients. In our study, the KRAS, BRAF, and PIK3CA mutation status of 485 GC patients were analyzed by Sanger sequencing. Kaplan-Meier analysis was used to plot survival curves according to different genotypes. The results show that the frequency of KRAS, BRAF and PIK3CA mutations were 4.1%, 1.2% and 3.5%, respectively. BRAF mutations were significantly concentrated in stage III and IV gastric cancer (P=0.009). KRAS G12V mutation carriers have much shorter OS than other mutation carriers and wild-type group patients (P=0.013). In conclusion, only the KRAS G12V mutation has an adverse effect on patient survival.

Keywords: KRAS, BRAF, PIK3CA, Mutation, Gastric cancer

Citation styles

APA

Fu, X.H., Chen, Z.T., Wang, W.H., Fan, X.J., Huang, Y., Wu, X.B., Huang, J.L., Wang, J.X., Lin, H.J., Tan, X.L., Wang, L., Wang, J.P. (2019). KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. Journal of Cancer, 10(4), 821-828. https://doi.org/10.7150/jca.27899.

ACS

Fu, X.H.; Chen, Z.T.; Wang, W.H.; Fan, X.J.; Huang, Y.; Wu, X.B.; Huang, J.L.; Wang, J.X.; Lin, H.J.; Tan, X.L.; Wang, L.; Wang, J.P. KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. J. Cancer 2019, 10 (4), 821-828. DOI: 10.7150/jca.27899.

NLM

CSE

Fu XH, Chen ZT, Wang WH, Fan XJ, Huang Y, Wu XB, Huang JL, Wang JX, Lin HJ, Tan XL, Wang L, Wang JP. 2019. KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. J Cancer. 10(4):821-828.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.